Sinclair Pharma in-line full year results thanks to uplift in facials
19th Sep 2013 08:25
Profits shot up at dermatology focused drug company Sinclair IS Pharma thanks to strong growth of its aesthetic non-surgical facelift products. Adjusted profit before tax and exceptional items soared 69% to £4.3m on sales up 7.7% to £55.4m. However, exceptional charges of £16.8m, including a £15.
Read moreThursday broker round-up UPDATE
19th Sep 2013 08:20
ASOS: Canaccord Genuity increases target price from 3400p to 6200p and upgrades to buy. Associated British Foods: Jefferies raises target price from 1650p to 1750p and retains a hold recommendation. Barclays: Alphavalue upgrades from add to buy with a target price of 344.20p. BHP Billiton: Nomura
Read moreSinclair IS Pharma's annual revenue increases
11th Jul 2013 10:26
Sinclair IS Pharma's shares surged after the company reported a rise in annual revenue supported by growth of its dermatology brands. The specialty pharmaceutical company posted revenue of £55.4m for the year to end of June, a like-for-like increase of 4.0%. Dermatology brands contributed 80% of g
Read moreWednesday broker round-up UPDATE
27th Feb 2013 08:11
: Panmure Gordon reduces target price from 2159p to 1742p and reiterates its hold recommendation. Antofagasta: JP Morgan cuts target price from 1485p to 1400p, while retaining its overweight rating. Barclays: Numis raises target price from 351p to 400p and upgrades to buy. BT Group: UBS moves tar
Read moreTuesday broker round-up UPDATE
19th Feb 2013 07:30
Admiral Group: Investec takes target price from 570p to 582p, but still recommends selling. Advanced Medical Solutions: Investec upgrades from hold to buy with a target price of 68p. African Barrick Gold: Canaccord Genuity reduces target price from 360p to 305p keeping a hold rating. Anglo Americ
Read moreThursday broker round-up UPDATE
10th Jan 2013 07:10
Afren: Morgan Stanley takes target price from 215p to 220p and reiterates an overweight rating. Alent: Bank of America starts with a target price of 370p and a buy recommendation. Associated British Foods: Goldman Sachs moves its target price from 1160p to 1190p and maintains a sell rating. AVEVA
Read moreDS Smith exec raises one million quid to pay taxes
20th Dec 2012 16:25
Stephen Dryden, the Finance Director of recycled packaging supplier DS Smith, exercised options in the company on Wednesday and subsequently sold half of them for nearly one million pounds. The executive, appointed to the board in April 2008, exercised nil-cost options for 878,903 shares, then sold
Read moreSinclair IS Pharma joins forces with Biocodex to crack new markets
19th Dec 2012 10:52
Sinclair IS Pharma has signed a 10-year deal with Biocodex to expand its dermatology portfolio in Russia, Turkey and Europe's Benelux countries. Biocodex, an independent French pharmaceutical company, will support in the importation and distribution of Sinclair products to wholesalers. The compan
Read moreGeronimo Inns MD offloads shares in parent group Young's & Co
18th Dec 2012 17:00
Rupert Clevely, the Managing Director of Young's & Co Brewery's Geronimo Inns division, sold nearly half a million pounds-worth of shares in the pubs group on Tuesday. Clevely, who co-founded Geronimo Inns, sold 62,688 shares in Young's & Co at 701.3573p a pop, earning himself a total of £439,667.
Read moreFriday broker round-up - UPDATE
19th Oct 2012 09:00
Aggreko: Jefferies keeps buy rating and 2,800p target; Seymour Pierce keeps buy rating and 2,500p target; Panmure Gordon cuts target from 2,228p to 2,159p, hold rating unchanged. Alliance Pharma: umps upgrades to buy, target lifted from 32p to 37p. Avacta: Panmure Gordon keeps buy rating and 1.75p
Read moreMonday broker round-up
1st Oct 2012 08:58
Barclays: Liberum Capital upgrades to buy, target lifted from 210p to 245p. British American Tobacco: Investec upgrades to buy. Capital & Counties: Seymour Pierce downgrades from buy to add, 233p target kept. Charles Stanley: Peel Hunt downgrades to hold. Electrocomponents: Panmure Gordon downgr
Read moreSinclair IS Pharma builds on dermatology portfolio
1st Oct 2012 08:55
Sinclair IS Pharma said it had secured a long term distribution agreement for three dermatology products. The 100 year deal with Valeant Pharmaceuticals will the see Sinclair making an upfront payment of €9.0m for the rights. The company will make additional sales-based payments over the life of
Read moreSinclair driven by Asian sales
10th Jul 2012 13:59
Pharmaceutical firm Sinclair IS Pharma saw a big jump in revenues in the last year driven by international sales. In a trading statement the firm said it expected revenue for the year to the end of June to have grown by 56% to reach £51.3m Like-for-like revenue growth was expected to be 11.3% for
Read moreTuesday broker round-up - UPDATE
10th Jul 2012 08:18
WPP: JP Morgan upgrades to outperform from neutral. AMEC: BarCap raises target from 1,340p to 1,350p, underweight rating kept. ASOS: Peel Hunt keeps buy rating and 1,800p target. AstraZeneca: BarCap keeps equal weight rating. Betfair: Nomura cuts target from 1,070p to 946p, buy rating unchanged.
Read moreTullow non-exec makes double purchase following oil discovery
10th May 2012 16:00
Simon Thompson, a Non-Executive Director of FTSE 100 resources company Tullow Oil, has added 8,419 shares to his stake in the firm following its announcement of a recent discovery. The discovery saw the company source further oil in the first exploration well at one of its Kenyan projects, increasi
Read more